Helsinn nominated as a Swiss Biotech Success Story 2019/2020 by the Swiss Biotech Association

 

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that it is one of the companies to have been nominated as one of the Swiss Biotech Association’s Biotech Success Stories for the period.

Helsinn was nominated alongside Actelion and Debiopharm, as well as three foundations Venture Foundation, Venturelab and Venture Kick. For the first time, the nominees include an individual.

Each year, the Swiss Biotech Association presents companies with the “Swiss Biotech Success Stories” awards in recognition of outstanding achievements.

Riccardo Braglia, Helsinn Group Vice Chairman and Chief Executive Officer commented: “We’re delighted to be part of the continued success of the Swiss Biotech industry. Switzerland is a world-leading hub for biopharma thanks to a unique set of factors: diversity, the excellence of the science base, strong infrastructure and excellent technology transfer and a collaborative approach, leading to a healthy pipeline of scientific development. These are all factors which are highly prized at Helsinn and we are very pleased that the Swiss Biotech Association has recognized us for our strength.”

Helsinn is an exclusive pharmaceutical gathering with a broad arrangement of advertised malignant growth care items and a hearty medication advancement pipeline. Since 1976, Helsinn has been improving the regular daily existences of patients, guided by center family estimations of regard, uprightness and quality. The Group works crosswise over pharmaceuticals, biotechnology, medicinal gadgets and wholesome enhancements and has skill in research, advancement, fabricated and the commercialization of helpful and steady consideration items for malignancy, torment and irritation and gastroenterology. In 2016, Helsinn made the Helsinn Investment Fund to help beginning time speculation openings in regions of neglected patient need. The organization is headquartered in Lugano, Switzerland, with working backups in Switzerland, Ireland, the U.S., Monaco, and China, just as item nearness in around 190 nations all inclusive.